The mTOR inhibitor everolimus is currently approved for lung and gastrointestinal NET and pNET, but shows promise for use in the adjuvant setting and as combination therapy. The gene discussed is MTOR; the disease is digestive system neuroendocrine tumor, grade 1/2.